Journal of the American Chemical Society
Communication
R.; Gagnon, M.; Juteau, H.; Laliberte, S.; MacKay, B.; Gareau, Y.
(Merck, USA). U.S. Pat. Appl. 2008/0188521 A1, Aug 7, 2008.
(16) Vidler, L. R.; Filippakopoulos, P.; Fedorov, O.; Picaud, S.;
Martin, S.; Tomsett, M.; Woodward, H.; Brown, N.; Knapp, S.;
Hoelder, S. J. Med. Chem. 2013, 56, 8073.
(17) See, for example: (a) Upadhayaya, R. S.; Shinde, P. D.; Sayyed,
A. Y.; Kadam, S. A.; Bawane, A. N.; Poddar, A.; Plashkevych, O.;
Foldesi, A.; Chattopadhyaya, J. Org. Biomol. Chem. 2010, 8, 5661.
̈
ACKNOWLEDGMENTS
■
We thank Kelsey Miles for X-ray crystallographic determi-
nation. We are grateful for financial support from the NIH
(R01-GM100143). Analytical instrumentation was partially
funded by the National Science Foundation (CHE-1048642,
CHE-9208463, CHE-0342998, CHE-9974839, CHE-9304546)
and National Institutes of Health (NIH 1 S10 RR13866-01)
(b) Upadhayaya, R. S.; Lahore, S. V.; Sayyed, A. Y.; Dixit, S. S.; Shinde,
P. D.; Chattopadhyaya, J. Org. Biomol. Chem. 2010, 8, 2180.
(c) Upadhayaya, R. S.; Shinde, P. D.; Kadam, S. A.; Bawane, A. N.;
Sayyed, A. Y.; Kardile, R. A.; Gitay, P. N.; Lahore, S. V.; Dixit, S. S.;
REFERENCES
■
(1) For selected reviews, see: (a) Klinman, J. P. J. Biol. Chem. 1996,
271, 27189. (b) Mure, M. Acc. Chem. Res. 2004, 37, 131.
(2) (a) Wendlandt, A. E.; Stahl, S. S. Org. Lett. 2012, 14, 2850.
(b) Largeron, M.; Fleury, M.-B. Angew. Chem., Int. Ed. 2012, 51, 5409.
(c) Largeron, M.; Fleury, M.-B. Science 2013, 339, 43.
(3) Wendlandt, A. E.; Stahl, S. S. J. Am. Chem. Soc. 2014, 136, 506.
(4) For leading references to other catalytic methods for
dehydrogenation of tetrahydroquinolines, see: (a) Yamaguchi, K.;
Mizuno, N. Angew. Chem., Int. Ed. 2003, 42, 1480. (b) Yamaguchi, R.;
Ikeda, C.; Takahashi, Y.; Fujita, K.-i. J. Am. Chem. Soc. 2009, 131, 8410.
(c) Wu, J.; Talwar, D.; Johnston, S.; Yan, M.; Xiao, J. Angew. Chem.,
Int. Ed. 2013, 52, 6983. (d) Chakraborty, S.; Brennessel, W. W.; Jones,
W. D. J. Am. Chem. Soc. 2014, 136, 8564.
Foldesi, A.; Chattopadhyaya, J. Eur. J. Med. Chem. 2011, 46, 1306.
̈
(18) Upadhayaya, R. S.; Dixit, S. S.; Foldesi, A.; Chattopadhyaya, J.
̈
Bioorg. Med. Chem. Lett. 2013, 23, 2750.
(19) (a) Utsugi, T.; Aoyagi, K.; Asao, T.; Okazaki, S.; Aoyagi, Y.;
Sano, M.; Wierzba, K.; Yamada, Y. Jpn. J. Cancer Res. 1997, 88, 992.
(b) Okazaki, S.; Asao, T.; Wakida, M.; Ishida, K.; Washinosu, M.;
Utsugi, T.; Yamada, Y. (Taiho Pharmaceutical Co., Japan). Eur. Pat.
0 713 870 B1, July 18, 2001. (c) Fujimoto, S. Biol. Pharm. Bull. 2007,
30, 1923.
(5) Through reaction screening, it was determined that 1.0 mol %
Bu4NI was optimal in the case of both the Fe and Ru catalysts. See
Supporting Information for additional details.
(6) For examples of homo- and heteroleptic Ru-phd complexes, see:
(a) Nguyen, F.; Anson, F. C. Electrochim. Acta 1998, 44, 239.
(b) Poteet, S. A.; Majewski, M. B.; Breitbach, Z. S.; Griffith, C. A.;
Singh, S.; Armstrong, D. W.; Wolf, M. O.; MacDonnell, F. M. J. Am.
Chem. Soc. 2013, 135, 2419. (c) Poteet, S. A.; MacDonnell, F. M.
Dalton Trans. 2013, 42, 13305. (d) Parakh, P.; Gokulakrishnan, S.;
Prakash, H. Sep. Purif. Technol. 2013, 109, 9.
(7) Ru-phd complexes have been applied previously as catalysts for
NADH oxidation: (a) Goss, C. A.; Abruna, H. D. Inorg. Chem. 1985,
̃
24, 4263. (b) Hilt, G.; Steckhan, E. J. Chem. Soc., Chem. Commun.
1993, 1706. (c) Rivera, N.; Colon
Bioenerg. 1994, 34, 169. (d) Wu, Q.; Maskus, M.; Pariente, F.;
Tobalina, F.; Fernandez, V. M.; Lorenzo, E.; Abruna, H. D. Anal.
́
, Y.; Guadalupe, A. R. Bioelectrochem.
́
̃
Chem. 1996, 68, 3688. (e) Hilt, G.; Lewall, B.; Montero, G.; Utley, J.
H. P.; Steckhan, E. Liebigs Ann. 1997, 2289. (f) Hilt, G.; Jarbawi, T.;
Heineman, W. R.; Steckhan, E. Chem.Eur. J. 1997, 3, 79.
(g) Yokoyama, K.; Ueda, Y.; Nakamura, N.; Ohno, H. Chem. Lett.
2005, 34, 1282. (h) Pinczewska, A.; Sosna, M.; Bloodworth, S.;
Kilburn, J. D.; Bartlett, P. N. J. Am. Chem. Soc. 2012, 134, 18022.
(8) For a recent review of this area, see: Piera, J.; Backvall, J.-E.
̈
Angew. Chem., Int. Ed. 2008, 47, 3506.
(9) For a specific recent example, see: Volla, C. M. R.; Backvall, J.-E.
̈
Angew. Chem., Int. Ed. 2013, 52, 14209.
(10) For leading references, see: (a) Sakamoto, H.; Funabiki, T.;
Yoshida, S.; Tarama, K. Bull. Chem. Soc. Jpn. 1979, 52, 2760.
(b) Tsuruya, S.; Yanai, S.-i.; Masai, M. Inorg. Chem. 1986, 25, 141.
(c) Sakata, K.; Kikutake, T.; Shigaki, Y.; Hashimoto, M.; Ogawa, H. I.;
Kato, Y. Inorg. Chim. Acta 1988, 144, 1. (d) Simandi, L. I.; Simandi, T.
́ ́
M.; May, Z.; Besenyei, G. Coord. Chem. Rev. 2003, 245, 85.
(11) See Supporting Information for details.
(12) The combinations of Co(salophen) with Zn(OTf)2/phd and
with the [Fe(phd)3]2+ complex were also tested. Good results were
obtained with Zn(OTf)2/phd/Co(salophen); however, the results did
not surpass those of [Ru(phd)3]2+/Co(salophen).
(13) Photoexcitation of Ru-phd complexes is typically thought to
terminate in non-radiative decay pathways arising from the semi-
quinone structure. See refs 6b,c.
(14) In general, the use of methanol as a solvent improved yields in
the oxidation of 2-substituted tetrahydroquinolines. For other
substrates, acetonitrile was the preferred solvent.
́
(15) (a) Delorme, D.; Dube, D.; Ducharme, Y.; Grimm, E. L.;
Friesen, R.; Lepine, C. (Merck Frosst, Canada). U.S. Pat. 5,552,437,
Sept 3, 1996. (b) Grimm, E. L.; Ducharme, Y.; Frenette, R.; Friesen,
11913
dx.doi.org/10.1021/ja506546w | J. Am. Chem. Soc. 2014, 136, 11910−11913